

- **Full Name:** Se-Hoon Lee
- **Current Position & Affiliation:** Professor, Samsung Medical Center
- **Country:** Korea

• Educational Background:

Year	Institute	Position
1996	College of Medicine, Seoul National University, Seoul, Korea	M.D.
2008	Graduate School, Seoul National University, Seoul, Korea	Ph.D.
2001	Seoul National University Hospital, Seoul, Korea	Residency
2002	Seoul National University Hospital, Seoul, Korea	Fellowship
2004	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Fellowship

• Professional Experience:

Year	Institute	Position
2005~2015	Seoul National University Hospital, Seoul, Korea	Assistant and Associate Professor
2009~2010	Dana-Farber Cancer Institute, Boston, MA (Harvard Medical School) & Broad Institute, Cambridge, MA	Visiting Scholar
2015~	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Professor

- **Professional Organizations:** Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

• Main Scientific Publications:

- Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. *N Engl J Med*. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Epub ahead of print. PMID: 37272513.
- Lee SH, Kim Y, Jeon BN, Kim G, Sohn J, Yoon Y, Kim S, Kim Y, Kim H, Cha H, Lee NE, Yang H, Chung JY, Jeong AR, Kim YY, Kim SG, Seo Y, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park H, Yoon KW. Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8⁺ T Cells. *Adv Sci (Weinh)*. 2023 Jun;10(17):e2204378. doi: 10.1002/advs.202204378. Epub 2023 Apr 25. PMID: 37097643; PMCID: PMC10265102. [first author]
- Hong TH, Bang YH, Joe C, Hwang S, Lee B, Lee N, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Lee SH. Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer. *J Thorac Oncol*. 2023 Apr 5:S1556-0864(23)00482-3. doi: 10.1016/j.jtho.2023.03.024. Epub ahead of print. PMID: 37028596. [corresponding author]
- Kim JY, Cha H, Kim K, Sung C, An J, Bang H, Kim H, Yang JO, Chang S, Shin I, Noh SJ, Shin I, Cho DY, Lee SH, Choi JK. MHC II immunogenicity shapes the neoepitope landscape in human tumors. *Nat Genet*. 2023 Jan 9. doi: 10.1038/s41588-022-01273-y. Epub ahead of print. PMID: 36624345. [corresponding author]
- Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2022 Mar 10;JCO2102010. doi: 10.1200/JCO.21.02010. Epub ahead of print. PMID: 35271299. [corresponding author]

6. Lee SH, Cho SY, Yoon Y, Park C, Sohn J, Jeong JJ, Jeon BN, Jang M, An C, Lee S, Kim YY, Kim G, Kim S, Kim Y, Lee GB, Lee EJ, Kim SG, Kim HS, Kim Y, Kim H, Yang HS, Kim S, Kim S, Chung H, Moon MH, Nam MH, Kwon JY, Won S, Park JS, Weinstock GM, Lee C, Yoon KW, Park H. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. **Nat Microbiol.** 2021 Jan 11. doi: 10.1038/s41564-020-00831-6. Epub ahead of print. PMID: 33432149. [first author]
7. Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. **J Immunother Cancer.** 2020 Oct;8(2):e001199. doi: 10.1136/jitc-2020-001199. PMID: 33077514; PMCID: PMC7574938. [corresponding author]
8. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. **Ann Oncol.** 2020. doi: 10.1016/j.annonc.2020.04.004. [corresponding author]
9. Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. **Nat Commun.** 2020 Feb 19;11(1):951. doi: 10.1038/s41467-020-14562-z. PubMed PMID: 32075964; PubMed Central PMCID: PMC7031381. [corresponding author]
10. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. **Nat Commun.** 2019 Sep 19;10(1):4278. [corresponding author]
11. Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. **J Thorac Oncol.** 2019 Jun 10. [Epub ahead of print] [first author]